Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.

The team will enrol healthy volunteers aged between 18 – 55, who, if they pass screening, will be the first humans to test the new vaccine, called ChAdOx1 nCoV-19. The trial will provide valuable information on the safety aspects of the vaccine, as well as its ability to generate an immune response against the virus. Interested individuals can volunteer to participate on the COVID-19 vaccine website.

The trial, a collaboration between the University’s Jenner Institute and Oxford Vaccine Group clinical teams, will recruit up to 510 volunteers, who will receive either the ChAdOx1 nCoV-19 vaccine or a control injection for comparison. Whilst the team will start screening people now to see if they are eligible to take part in the study, participants will not receive the vaccine for some weeks. Detailed preclinical work is being done and the vaccine is being manufactured to clinical grade standard at the Clinical Biomanufacturing Facility at Oxford University. The trial has been approved by UK regulators and ethical reviewers. Researchers are working as quickly as possible to get the vaccine ready to be used in the trial, which includes further preclinical investigations and production of a larger number of doses of the vaccine.

Read the full story on the University of Oxford website

Similar stories

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.

New research sheds light on how ultrasound could be used to treat psychiatric disorders

A new study in macaque monkeys has shed light on which parts of the brain support credit assignment processes (how the brain links outcomes with its decisions) and, for the first time, how low-intensity transcranial ultrasound stimulation (TUS) can modulate both brain activity and behaviours related to these decision-making and learning processes.

Dramatic fall in hospital admissions for child infections since start of Covid-19 pandemic

Since the onset of the Covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

Christoph Treiber awarded ERC Starting Grant to investigate the origins of behavioural diversity

Congratulations are in order for postdoctoral research scientist Dr Christoph Treiber who has been awarded a Starting Grant from the European Research Council. His funded project will investigate the genetic components that may contribute to diversity of brain function and behaviour.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.